Samardzic Janko, Smits Anne, Spriet Isabel, Soldatovic Ivan, Atkinson Andrew, Bajcetic Milica, Van Den Anker John N, Allegaert Karel
Institute of Pharmacology, Clinical Pharmacology and Toxicology, Medical Faculty, University of Belgrade, 11000 Belgrade, Serbia; Division of Pediatric Pharmacology and Pharmacometrics, University of Basel Children's Hospital, 4056 Basel, Switzerland.
Department of Development and Regeneration, KU Leuven, 3000 Leuven, Belgium; Neonatal Intensive Care Unit, University Hospitals Leuven, 3000 Leuven, Belgium.
Biomed Res Int. 2016;2016:1974972. doi: 10.1155/2016/1974972. Epub 2016 Aug 21.
Substantial interassay variability (up to 20%) has been described for vancomycin immunoassays in adults, but the impact of neonatal matrix is difficult to quantify because of blood volume constraints in neonates. However, we provide circumstantial evidence for a similar extent of variability. Using the same vancomycin dosing regimens and confirming similarity in clinical characteristics, vancomycin trough concentrations measured by PETINIA (2011-2012, n = 400) were 20% lower and the mean difference was 1.93 mg/L compared to COBAS (2012-2014, n = 352) measurements. The impact of vancomycin immunoassays in neonatal matrix was hereby suggested, supporting a switch to more advanced techniques (LC-MS/MS).
已有报道称，成人万古霉素免疫测定存在显著的批间差异（高达20%），但由于新生儿血容量受限，新生儿样本基质的影响难以量化。然而，我们提供了间接证据表明存在相似程度的差异。采用相同的万古霉素给药方案，并确认临床特征相似，与COBAS（2012 - 2014年，n = 352）测量结果相比，PETINIA（2011 - 2012年，n = 400）测定的万古霉素谷浓度低20%，平均差异为1.93 mg/L。由此表明了万古霉素免疫测定在新生儿样本基质中的影响，支持转向更先进的技术（液相色谱 - 串联质谱法）。
